cannabinoid e.g., a single cannabinoid such as CBD, or combination of cannabinoids active ingredient portion of a composition of the disclosure comprises about 0.1 %, about 0.2 %, about 0.3 %, about 0.4 %, about 0.5 %, about 0.6 %, about 0.7 %, about 0.8 %, about 0.9 %, about 1 %, about 1.5 %, about 2 %, about 2.5 %, about 3 %, about 3.5 %, about 4 %, about 4.5 %, about 5 %, about 5.5 %, about 6 %, about 6.5 %, about 7 %, about 7.5 %, about 8 %, about 8.5 %, about 9 %, about 9.5 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, about 15 %, about 16 %, about 17 %, about 18 %, about 19 %, about 20 %, about 21 %, about 22 %, about 23 %, about 24 %, about 25 %, about 27 %, the active ingredient portion of a composition comprises at least about 0.1 %, at least about 0.2 %, at least about 0.3 %, at least about 0.4 %, at least about 0.5 %, at least about 0.6 %, at least about 0.7 %, at least about 0.8 %, at least about 0.9 %, at least about 1 %, at least about 1.5 %, at least about 2 %, at least about 2.5 %, at least about 3 %, at least about 3.5 %, at least about 4 %, at least about 4.5 %, at least about 5 %, at least about 5.5 %, at least about 6 %, at least about 6.5 %, at least about 7 %, at least about 7.5 %, at least about 8 %, at least about 8.5 %, at least about 9 %, at least about 9.5 %, at least about 10 %, at least about 11 %, at least about 12 %, at least about 13 %, at least about 14 the active ingredient portion of a composition of the disclosure comprises about 19.2 % of cannabinoid (e.g., a single cannabinoid such as CBD, or combination of cannabinoids), by weight of the active ingredient portion
Through genuine indifference
These treatments are available at many leading healthcare providers around the world today
Edison Biotechnology Institute, 3 Massachusetts General Hospital/Harvard Medical School, 4 Massachusetts General Hospital Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global concern due to its increasing frequency and risk for co-morbidities such as cirrhosis, hepatocellular carcinoma, and extrahepatic metabolic and endocrine complications
10.1016/s1297-319x(03)00014-9 87 SiddiquiR.MakhloufZ.AlharbiA
